Formulation and Drug Delivery

Avacta, Daewoong Pharmaceutical Form Immunotherapy Joint Venture

January 08, 2020

The joint venture will develop next-generation cell and gene therapies incorporating Affimer proteins.

ProBioGen Inks Commercial GlymaxX Deal with Roche

January 08, 2020

Roche will apply ProBioGen’s proprietary GlymaxX technology to boost the antibody-dependent cellular cytotoxicity activity of antibodies.

Johnson & Johnson to Acquire Taris Biomedical

January 03, 2020

Through the acquisition, Johnson & Johnson will gain access to Taris’ lead clinical-stage product, TAR-200.

Fresh Thinking in Biologic Drug Formulation

January 02, 2020

Biologics raise unique formulation and development challenges, and industry is still on a learning curve to get the best out of these diverse and complex therapies.

Development of Taste-Masked Oral Reconstitutable Suspension of Cetirizine Dihydrochloride

January 02, 2020

The aim of this study was to prepare taste-masked drug-resin complex using ion exchange resin Kyron T-134.

Pharma’s Decade in Brief

January 02, 2020

As a new decade has begun, this editorial reviews some of the biggest, brightest, and boldest happenings from the industry over the past 10 years.

Packing a Punch in Paris

January 02, 2020

PTE looks ahead to 2020’s edition of Pharmapack-the pharma industry’s dedicated packaging and drug delivery event.

Devices Under Scrutiny

January 02, 2020

Without careful consideration and understanding, new regulations for medical devices could lead to the withdrawal of combination products from the market.

Sanofi Expands Pandemic Flu Vaccine Manufacturing

December 12, 2019

Sanofi Pasteur will expand clinical development and manufacturing of an adjuvanted recombinant pandemic vaccine at its site in Pennsylvania.

Stevanato Group Breaks Ground on New Technology Excellence Center

December 06, 2019

The new Technology Excellence Center, located in Boston, MA, will further the company’s presence in the United States biopharma drug development landscape.